(Bloomberg) — Nestle SA agreed to buy Aimmune Therapeutics Inc. in a $2.6 billion deal, adding a leader in the treatment of peanut allergies in its biggest health-science push yet.The Swiss owner of Nespresso will pay $34.50 a share for the U.S. biotech firm, almost triple its market value. Aimmune makes Palforzia, the first regulatory-approved treatment to help reduce allergic reactions to peanuts in children and teens in the U.S.Chief Executive Officer Mark Schneider has been cultivating Nestle’s health-science arm while shedding slower-growing businesses in areas such as bottled water and sweets. Palforzia, which exposes patients to small doses of …read more
Source:: Yahoo Finance
